Study Evaluating Temsirolimus (CCI-779) In Breast Neoplasms
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms
Interventions: DRUG: Letrozole / Temsirolimus (CCI-779)|DRUG: Letrozole / Temsirolimus (CCI-779)|DRUG: Letrozole
Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators: Pfizer